|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chi KN, Bjartell A, Dearnaley D, Saad F,
Schröder FH, Sternberg C, Tombal B and Visakorpi T:
Castration-resistant prostate cancer: From new pathophysiology to
new treatment targets. Eur Urol. 56:594–605. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sturge J, Caley MP and Waxman J: Bone
metastasis in prostate cancer: Emerging therapeutic strategies. Nat
Rev Clin Oncol. 8:357–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carthew RW and Sontheimer EJ: Origins and
Mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
9
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, et
al: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar :
|
|
11
|
Kojima S, Enokida H, Yoshino H, Itesako T,
Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, et
al: The tumor-suppressive microRNA-143/145 cluster inhibits cell
migration and invasion by targeting GOLM1 in prostate cancer. J Hum
Genet. 59:78–87. 2014. View Article : Google Scholar
|
|
12
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014.PubMed/NCBI
|
|
14
|
Goto Y, Nishikawa R, Kojima S, Chiyomaru
T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa
M, et al: Tumour-suppressive microRNA-224 inhibits cancer cell
migration and invasion via targeting oncogenic TPD52 in prostate
cancer. FEBS Lett. 588:1973–1982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goto Y, Kojima S, Nishikawa R, Enokida H,
Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki
N: The microRNA-23b/27b/24-1 cluster is a disease progression
marker and tumor suppressor in prostate cancer. Oncotarget.
5:7748–7759. 2014.PubMed/NCBI
|
|
16
|
Goto Y, Kurozumi A, Enokida H, Ichikawa T
and Seki N: Functional significance of aberrantly expressed
microRNAs in prostate cancer. Int J Urol. 22:242–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukumoto I, Hanazawa T, Kinoshita T,
Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida
H, Nakagawa M, et al: MicroRNA expression signature of oral
squamous cell carcinoma: Functional role of microRNA-26a/b in the
modulation of novel cancer pathways. Br J Cancer. 112:891–900.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baylin SB, Esteller M, Rountree MR,
Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA
methylation, chromatin formation and gene expression in cancer. Hum
Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sandhu R, Rivenbark AG and Coleman WB:
Loss of post-transcriptional regulation of DNMT3b by microRNAs: A
possible molecular mechanism for the hypermethylation defect
observed in a subset of breast cancer cell lines. Int J Oncol.
41:721–732. 2012.PubMed/NCBI
|
|
22
|
Börno ST, Fischer A, Kerick M, Fälth M,
Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, et al:
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative
prostate cancers implicate an EZH2-dependent mechanism with miR-26a
hypermethylation. Cancer Discov. 2:1024–1035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koh CM, Iwata T, Zheng Q, Bethel C,
Yegnasubramanian S and De Marzo AM: Myc enforces overexpression of
EZH2 in early prostatic neoplasia via transcriptional and
post-transcriptional mechanisms. Oncotarget. 2:669–683.
2011.PubMed/NCBI
|
|
24
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang B, Liu XX, He JR, Zhou CX, Guo M, He
M, Li MF, Chen GQ and Zhao Q: Pathologically decreased miR-26a
antagonizes apoptosis and facilitates carcinogenesis by targeting
MTDH and EZH2 in breast cancer. Carcinogenesis. 32:2–9. 2011.
View Article : Google Scholar
|
|
26
|
Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang
JR, Zeng C and Zhuang SM: MicroRNA-26a/b and their host genes
cooperate to inhibit the G1/S transition by activating the pRb
protein. Nucleic Acids Res. 40:4615–4625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sparmann A and van Lohuizen M: Polycomb
silencers control cell fate, development and cancer. Nat Rev
Cancer. 6:846–856. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raman JD, Mongan NP, Tickoo SK, Boorjian
SA, Scherr DS and Gudas LJ: Increased expression of the polycomb
group gene, EZH2, in transitional cell carcinoma of the bladder.
Clin Cancer Res. 11:8570–8576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fu X, Meng Z, Liang W, Tian Y, Wang X, Han
W, Lou G, Wang X, Lou F, Yen Y, et al: miR-26a enhances miRNA
biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth
and metastasis. Oncogene. 33:4296–4306. 2014. View Article : Google Scholar
|
|
33
|
Heo I, Joo C, Cho J, Ha M, Han J and Kim
VN: Lin28 mediates the terminal uridylation of let-7 precursor
MicroRNA. Mol Cell. 32:276–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Viswanathan SR, Daley GQ and Gregory RI:
Selective blockade of microRNA processing by Lin28. Science.
320:97–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hagan JP, Piskounova E and Gregory RI:
Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in
mouse embryonic stem cells. Nat Struct Mol Biol. 16:1021–1025.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piskounova E, Polytarchou C, Thornton JE,
LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D and Gregory RI:
Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct
mechanisms. Cell. 147:1066–1079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu C, Kelnar K, Vlassov AV, Brown D, Wang
J and Tang DG: Distinct microRNA expression profiles in prostate
cancer stem/progenitor cells and tumor-suppressive functions of
let-7. Cancer Res. 72:3393–3404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nadiminty N, Tummala R, Lou W, Zhu Y, Shi
XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, et al: MicroRNA let-7c
is downregulated in prostate cancer and suppresses prostate cancer
growth. PLoS One. 7:e328322012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie C, Huang L, Xie S, Xie D, Zhang G,
Wang P, Peng L and Gao Z: LARP1 predict the prognosis for
early-stage and AFP-normal hepatocellular carcinoma. J Transl Med.
11:2722013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mura M, Hopkins TG, Michael T, Abd-Latip
N, Weir J, Aboagye E, Mauri F, Jameson C, Sturge J, Gabra H, et al:
LARP1 post-transcriptionally regulates mTOR and contributes to
cancer progression. Oncogene. Dec
22–2014.doi.org/10.1038/onc.2014.428 (Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tcherkezian J, Cargnello M, Romeo Y,
Huttlin EL, Lavoie G, Gygi SP and Roux PP: Proteomic analysis of
cap-dependent translation identifies LARP1 as a key regulator of
5′TOP mRNA translation. Genes Dev. 28:357–371. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meyuhas O and Kahan T: The race to
decipher the top secrets of TOP mRNAs. Biochim Biophys Acta. Sep
16–2014. View Article : Google Scholar : (Epub ahead of
print). PubMed/NCBI
|
|
43
|
Aoki K, Adachi S, Homoto M, Kusano H,
Koike K and Natsume T: LARP1 specifically recognizes the 3′
terminus of poly(A) mRNA. FEBS Lett. 587:2173–2178. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Andersen JN, Sathyanarayanan S, Di Bacco
A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur
W, et al: Pathway-based identification of biomarkers for targeted
therapeutics: Personalized oncology with PI3K pathway inhibitors.
Sci Transl Med. 2:43ra552010. View Article : Google Scholar
|
